endpts.com
Genfit's up to €185M royalty deal; J&J's Tremfya gets a Crohn's approval - Endpoints News
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Adult patients following Crohn's disease, Inflammatory bowel disease, Guselkumab, IL-23 inhibitor, and Research and clinical trials.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. Use the original source link for the full details.
The original article from endpts.com has the full details, including any study limitations or source context.
